• Diagnosis​ ​Info​ ​and​ ​General​ ​Questions

  FDA Gives Priority to Duchenne MD Therapy Golodirsen Review

  Posted by Community Member on February 20, 2019 at 7:51 pm

  The FDA is giving priority review to golodirsen, a potential Duchenne treatment for patients amenable to exon 53 skipping, Sarepta Therapeutics announced. Read more about this announcement here.

  What are your thoughts on this news?

  replied 1 Member · 0 Replies
• 0 Replies

Log In to Reply